Biotech Firm Prepares Antiviral Drug Trials as Measles Cases Surge Globally
Shelton, Monday, 31 August 2026.
With U.S. measles cases surpassing 2025 totals, NanoViricides is preparing Phase II clinical trials for NV-387, a broad-spectrum antiviral candidate showing strong efficacy against lethal infections.
Escalating Global Measles Outbreak
As of 27 August 2026, confirmed measles cases in the United States reached 2,903, surpassing the total of 2,289 recorded for all of 2025 [1]. This increase represents a significant rise in infection rates, calculated as 26.824 compared to the previous year [1]. Simultaneously, Bangladesh reported 19,218 confirmed measles cases and 99 fatalities between 15 March and 30 August 2026 [1]. In the 24 hours leading up to 30 August 2026 alone, Bangladesh recorded 1,151 suspected cases and 4 deaths, indicating a persistent outbreak despite vaccination campaigns [1]. Contributing to the vulnerability, US MMR vaccination rates declined from 95.2% in the 2019-2020 period to 92.4% in 2025-2026, falling below the 95% threshold required to block measles spread [1].
NanoViricides Clinical Trial Preparations
In response to the surge, NanoViricides, Inc. (NYSE American: NNVC) announced it is preparing Phase II clinical trials for its antiviral drug candidate NV-387 to treat measles [1]. NV-387 is a broad-spectrum antiviral that has demonstrated efficacy in animal models against multiple viruses, including measles, COVID-19, and influenza [1][2]. The company intends to submit the NV-387 Phase II protocol to the US FDA via an Investigational New Drug (IND) process, though no specific deadline for this submission has been provided [alert! ‘No specific deadline provided for IND submission’] [1]. The US FDA Office of Orphan Products Development previously granted NV-387 Rare Pediatric Disease Drug designation, qualifying the company for a potential Priority Review Voucher upon successful Marketing Application [1].
Market Reaction and Investment Outlook
Following announcements regarding progress toward Phase II clinical trials for NV-387, shares of NanoViricides jumped nearly 10% on 6 July 2026 [2]. Noble Capital initiated coverage of NNVC with an Outperform rating and a $6 price target, representing a potential 350% upside from valuation levels on 6 July 2026 [2]. Analysts expect the stock to be driven by progress in ongoing mpox and Ebola clinical trials, followed by the launch of the measles clinical program [2]. As of 5 July 2026, NNVC stock had recorded a year-to-date gain of approximately 21%, reflecting growing investor interest in the company’s broad-spectrum antiviral platform [2].